Published in Patient on August 01, 2016
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Skeletal complications of malignancy. Cancer (1997) 5.41
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (2011) 5.12
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Discrete choice experiments in health care. BMJ (2004) 2.98
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82
Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008. Patient (2010) 2.30
Bisphosphonates: clinical experience. Oncologist (2004) 2.12
Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer (2002) 1.98
Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist (2005) 1.76
The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care (2008) 1.56
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology (2004) 1.47
Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer (2012) 1.44
Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer (2000) 1.29
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol (2006) 1.28
A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage (2012) 1.17
Preferences for and experiences of family involvement in cancer treatment decision-making: patient-caregiver dyads study. Psychooncology (2013) 1.15
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy (2013) 1.10
Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics (2011) 1.04
Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol (2012) 1.03
Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract (2010) 1.01
Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review. Oncol Nurs Forum (2012) 0.96
Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ (2009) 0.94
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer (2010) 0.93
Patient preferences for treatments to delay bone metastases. Prostate (2014) 0.89
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer (2014) 0.88
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer (2013) 0.88
Are physicians and patients in agreement? Exploring dyadic concordance. Health Educ Behav (2013) 0.88
Quality of life and symptom end points in palliative bone metastases trials. Clin Oncol (R Coll Radiol) (2006) 0.85
Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. Breast Cancer Res Treat (2012) 0.84
Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess (2013) 0.84
Physicians' preferences for bone metastases drug therapy in the United States. Value Health (2015) 0.82
Older adults newly diagnosed with symptomatic myeloma and treatment decision making. Oncol Nurs Forum (2014) 0.80
Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer (2014) 0.76
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer (2013) 0.76
Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. Alzheimer Dis Assoc Disord (2009) 0.76
Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: A discrete choice experiment. Palliat Med (2015) 0.76
Physicians' preferences for bone metastases drug therapy in the United States. Value Health (2015) 0.82
A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. Value Health (2016) 0.77
Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis. Pharmacoeconomics (2016) 0.75
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Support Care Cancer (2017) 0.75